348 - Translation of CCR2-targeted PET imaging of head and neck cancer (ID 59) - Society of Nuclear Medicine and Molecular Imaging 2020 Annual Meeting

348 - Translation of CCR2-targeted PET imaging of head and neck cancer (ID 59)

Oncology: Basic & Translational -> Basic Science (O) 348

348 - Translation of CCR2-targeted PET imaging of head and neck cancer (ID 59)

Session Name

Basic Oncology & Translational III

Speakers

H. Luehmann

Authors

Presentation Topic

Oncology: Basic & Translational -> Basic Science (O)

Presentation Number

348

Previous Eposter

347 - The First in Human Study of ¹²⁴I-JS001 PET/CT & PET/MR Detecting PD-1 Expression In Patients with Melanoma (ID 57)

Next Eposters

349 - First-in-Human Study of a⁶⁴Cu-Labeled Long-acting Integrin αvβ3 Targeting Molecule⁶⁴Cu-NOTA-EB-RGD in Healthy Volunteers and GBM Patients (ID 55)

350 - Differential effect of an activating ESR1 mutation on endocrine therapy modulation of progesterone receptor expression measured with ¹⁸F-fluorofuranylnorprogesterone in ER+ breast cancer (ID 60)

351 - FDG PET/CT assessment to validate and determine prognostic value of new FIGO staging system 2018 in patients with squamous cell carcinoma of the uterine cervix. (ID 985)

352 - Prognostic value of pretreatment FDG PET/CT in uterine cervical cancer: significance of histopathological subtypes (ID 984)

353 - Voxelwise Repeatability of Quantitative ¹⁸F-FDG-PET/MRI Metrics in Malignant Solid Tumors of the Pelvis (ID 987)

354 - ¹⁸F-Fluciclovine PET/CT Use in the Evaluation of Epithelial Ovarian Cancer (ID 990)

355 - Prediction of chemotherapeutic response with volumetric parameters or texture features on FDG PET in recurrent gynecological malignancies (ID 986)

357 - ¹⁸F-Fluciclovine PET/CT Use in the Evaluation of Endometrial Cancer (ID 989)

358 - Role of functional imaging for response assessment with Lu177-DOTATATE therapy for neuroendocrine tumors (ID 301)

361 - Ablation Informed by Reconciliation of Stimulated Thyroglobulin and Post-Thyroidectomy Iodine Neck Uptake: Radiotheragnostic Management of Differentiated Thyroid Cancer. (ID 299)